Paul Kim - Fulgent Genetics Chief Officer
| FLGT Stock | USD 17.02 0.61 3.46% |
Executive
Mr. Paul Kim is Chief Financial Officer of the Company. Mr. Kim has served as Fulgent Chief Financial Officer since January 2016. Prior to his service for us, Mr. Kim served as Chief Financial Officer of Cogent from January 2004 until 2011. Mr. Kims past experience also includes service as the Chief Financial Officer of JNI Corporationrationration, or JNI, a publicly traded storage area network technology company, from September 2002 until December 2003, as Vice President, Finance and Corporationrationrate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from January 1998 until October 1999. From April 1996 to January 1998, Mr. Kim was the Corporationrationrate Controller for Interlink Computer Sciences, Inc., a publiclytraded enterprise software company. From January 1990 to April 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager since 2016.
| Age | 57 |
| Tenure | 9 years |
| Address | 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 |
| Phone | 626 350 0537 |
| Web | https://www.fulgentgenetics.com |
Latest Insider Transactions
Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.Paul Kim Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Kim against Fulgent Genetics stock is an integral part of due diligence when investing in Fulgent Genetics. Paul Kim insider activity provides valuable insight into whether Fulgent Genetics is net buyers or sellers over its current business cycle. Note, Fulgent Genetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fulgent Genetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Kim over a month ago Disposition of 1553 shares by Paul Kim of Fulgent Genetics at 18.3 subject to Rule 16b-3 | ||
Paul Kim over three months ago Disposition of 733 shares by Paul Kim of Fulgent Genetics at 22.833 subject to Rule 16b-3 | ||
Paul Kim over six months ago Disposition of 865 shares by Paul Kim of Fulgent Genetics at 29.33 subject to Rule 16b-3 | ||
Paul Kim over a year ago Acquisition by Paul Kim of 2142 shares of Fulgent Genetics subject to Rule 16b-3 |
Fulgent Genetics Management Efficiency
The company has return on total asset (ROA) of (0.0415) % which means that it has lost $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1435) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2025. Return On Capital Employed is likely to drop to -0.06 in 2025. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 35 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Zarak Khurshid | Guardant Health | N/A | |
| Jeffrey Novack | Caredx Inc | 42 | |
| Stacey Follon | Caredx Inc | N/A | |
| Terilyn Monroe | Guardant Health | 57 | |
| Phil Grinnell | Natera Inc | N/A | |
| Gretchen Weightman | Illumina | N/A | |
| Aaron Bloomer | EXACT Sciences | 38 | |
| James Thorburn | Twist Bioscience Corp | 68 | |
| Jerry Diffley | Natera Inc | N/A | |
| Jake MBA | EXACT Sciences | 51 | |
| Pat Leckman | Illumina | 60 | |
| Philip Binns | Agilent Technologies | N/A | |
| Roger Smith | T2 Biosystms | 60 | |
| CPA CFA | Caredx Inc | 55 | |
| Darl Moreland | Guardant Health | 65 | |
| John Kohl | Agilent Technologies | N/A | |
| Jenny Zheng | Illumina | N/A | |
| Yvonne Mackie | Agilent Technologies | N/A | |
| Joydeep MBA | Illumina | 53 | |
| Ankur CPA | Illumina | 48 | |
| Robert III | Waters | N/A | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 |
Fulgent Genetics Leadership Team
Elected by the shareholders, the Fulgent Genetics' board of directors comprises two types of representatives: Fulgent Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulgent. The board's role is to monitor Fulgent Genetics' management team and ensure that shareholders' interests are well served. Fulgent Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulgent Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doreen Ng, VP Office | ||
| DABMG FACMG, Chief Director | ||
| Paul Kim, Chief Officer | ||
| Ming Hsieh, Chairman of the Board and Presidentident, CEO | ||
| Natalie Prescott, General Officer | ||
| Lawrence MD, Chief Officer | ||
| Ray Yin, President Pharma | ||
| Brandon Perthuis, Chief Officer | ||
| Jian Xie, COO President | ||
| Ellen Tsui, Vice Resources | ||
| Jakub Sram, Vice Sales | ||
| Paul CPA, Chief Officer |
Fulgent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fulgent Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 335.22 M | ||||
| Shares Outstanding | 30.59 M | ||||
| Shares Owned By Insiders | 32.30 % | ||||
| Shares Owned By Institutions | 55.09 % | ||||
| Number Of Shares Shorted | 970.6 K | ||||
| Price To Earning | 3.95 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.